BodynHealth
Home Mail Home Online Ordering Phone Ordering Help Search
  
•   All About Flavay™

•   Flavay Plus™

•   What does it do?

•   Q&A

•   Accept No Substitutes

•   Comparative Analysis

•   Endorsements & 
Testimonials

•   Proven Safety

•   Directions for Use

•   Contact Us

•   How to Purchase
 
sitemap
Questions?

Have proper research studies proven Flavay's™ safety and effectiveness? and other frequently asked questions...

What is Flavay™?

How safe is Flavay™?

How does Flavay™ affect the liver?

Does Flavay™ have any contraindications?

Should I consult with my doctor before taking Flavay™?

Can the active ingredients in Flavay™ be obtained in food?

Is Flavay™ patented?

Have proper research studies proven Flavay's™ effectiveness?

"What is the difference between the terms, OPC and polyphenol? In some cases it appears synonymous and in others there appears to be a distinction. On some labels it will say OPC, but in the supplement facts, it says grape seed extract (vitis vinifera) 95% polyphenols. I am confused."

Are OPCs (or, proanthocyanidins) the same as "grape seed extract" or "pine bark extract" products?

Is Flavay™ the same as "grape seed extract" or "pine bark extract"?

Is Flavay™ the same as OPCs (or proanthocyanidins) in the marketplace?

Do you have additional questions about Flavay™?

Q. What is Flavay™?
A. Flavay™ is a highly specialized, nutritional complex of pairs and triples of a specific molecule called "flavan-3-ol," isolated from natural extracts, and that has been extensively tested and examined clinically for biological antioxidant protection, collagen strengthening, tissue rebuilding and other health producing outcomes. [More...]
 
Top
Q. How safe is Flavay™?
A. After more than 50 years of human use, no adverse effects have been observed. Furthermore, intensive biological, toxicological, pharmacological and analytical research was conducted for the purpose of registering it as a medicine in France and other countries in Europe. In one study, daily doses of up to 35,000 mg for six months were determined to cause no adverse effects. [More...]
 
Top
Q. How does Flavay™ affect the liver?
A.

Flavay™ helps protect hepatic capillaries (the smallest blood vessels in the liver) from free radical damage and activates liver antioxidant enzyme systems. A study of twenty patients with cirrhosis of the liver showed that a daily intake of 300 mg of Flavay™ can help to decrease capillary fragility of the liver.

 
Top
Q. Does Flavay™ have any contraindications?
A.

No, Flavay™ has no known contraindications (conditions under which it should not be used). Flavay™ is completely safe and nontoxic. In fact, clinical trials have been conducted in which pregnant women (troubled by varicose veins and other circulatory problems in the legs) safely used Flavay™. [More...]

If you are taking anticoagulant medication, you should ask your doctor whether you may also use Flavay™ as it will also decrease the reactivity ("stickiness") of blood platelets. [More...]

 
Top
Q. Should I consult with my doctor before taking Flavay™?
A.

Yes, please consult your doctor before starting any course of supplementation or diet change, particularly if you are currently under medical care. If you have or suspect you may have a health problem, you should consult your doctor.

If you are taking anticoagulant medication, you should ask your doctor whether you may also use Flavay™ as it will also decrease the reactivity ("stickiness") of blood platelets. [More...]

 
Top
Q. Can the active ingredients in Flavay™ be obtained in food?
A.

Yes and No.

The active flavan-3-ol molecules in Flavay™ can be found especially in the fibrous and woody parts of naturally-ripened, raw fruits and vegetables, and in the skins of seeds, nuts and fruits. Unfortunately, our fruits and vegetables are typically deficient of these active polyphenol molecules due to our modern methods of distributing food—which result in fruits and vegetables that have been harvested while unripe. Another cause for deficiency is cooking, which destroys the active polyphenols. What's more, the skins of seeds, nuts and fruits are the parts of our food that we generally discard or spit out.

Actually, the best "food" source is red wine. The active principles in Flavay™ are at the center of the curious phenomenon known as the "French Paradox." Red wine is a carrier of these healthy polyphenols. So, why not just drink red wine to get your daily dose of flavan-3-ol? Alcoholic beverages are not ideal as dietary supplements due to potential abuse, dependency and toxicity as a result of over consumption. And, while alcohol can compromise liver function, Flavay™ actually helps protect hepatic capillaries (the smallest blood vessels in the liver) from free radical damage and activates liver antioxidant enzyme systems. The point is that Flavay™ provides specific protection to the liver, and red wine does not.

So, while drinking some red wine is a reasonably healthy for most adults, the best way to guarantee a consistent daily intake of flavan-3-ol polyphenols is in its pure, concentrated form—Flavay™.

 
Top
Q. Is Flavay™ Patented?
A.

Yes, there are many patents. In 1948 Dr. Jack Masquelier received a French Patent which described a method to extract the active principles in Flavay™ from the bark of the pinus Maritima. In 1970 Dr. Masquelier received another French Patent which described an even more efficient extraction method of the active principles from the seeds of the vitis vinifera grapes. On October 6, 1987 Dr. Masquelier was awarded U.S. Patent No. 4,698,360 to describe the proanthocyanidins in Flavay™ for use as a powerful antioxidant, "which has a radical scavenger effect."

"[A] method for preventing and fighting the harmful biological effects of free radicals in the organism of warm blooded animals and more especially human beings, namely cerebral involution, hypoxia following atherosclerosis, cardiac or cerebral infarction, tumour promotion, inflammation, ischaemia, alterations of the synovial liquid, collagen degradation, among others. The method consists in administering to said animals and especially to human beings an amount, efficient against said effects, of a plant extract with a proanthocyanidins content which has a radical scavenger effect"—Dr. Jack Masquelier, U.S. Patent No. 4,698,360.

Flavay™ is the actual product—used in the experiments—by which Dr. Jack Masquelier established and patented the "radical scavenger effect."

However, consumers need to know that the marketplace is full of imitations, various “extracts” and derivative forms of Dr. Masquelier’s scientifically proven and patented complex. Unfortunately, many have used Dr. Masquelier’s name and research in unauthorized ways to promote a myriad of derivations. In fact, the other "leading brand" pine bark extract, compared to Flavay™ below, is an offshoot derived from Dr. Masquelier's authentic work and products. But, independent comparative testing demonstrates that the initial qualifying research conducted on the authentic products may not be automatically transferred to other commercial products. [More...]

 
Top
Q. Have proper research studies proven Flavay's™ effectiveness?
A. Yes, Flavay™ is backed by more than 50 years of research and human use, patents for therapeutic uses and extensive testing for safety. The original French and European brands (see Resivit™, Endotelon™ and Flavanbelow) were registered in France as over-the-counter medications and it has therefore been consumed in Europe under medical supervision for decades with no reports of adverse side effects. [More...]
 
Top
Q. "What is the difference between the terms, OPC and polyphenol? In some cases it appears synonymous and in others there appears to be a distinction. On some labels it will say OPC, but in the supplement facts, it says grape seed extract (vitis vinifera) 95% polyphenols. I am confused."
A.

It's confusing because these terms are used inaccurately in the marketplace. "95% polyphenols" is a meaningless expression in a scientific context. However, it does illustrate a problem: In most cases, the following terms are used interchangeably for commercial interests—or by mistake—and their differences have truly lost all scientific meaning in the marketplace:

bioflavonoids and flavonoids,
oligomeric proanthocyanidins (OPCs or PCOs), and
polyphenols.

Therefore, when reading product labels, magazine articles and many popular books, these scientific terms should be considered as generic words and not scientific whatsoever.

 
Top
Q. Are OPCs (or, proanthocyanidins) the same as "grape seed extract" or "pine bark extract" products?
A.

Yes (in the marketplace) and No (in the scientific context).

Because of commercial interests—or by mistake— the terms, OPCs and proanthocyanidins, have truly lost all of their scientific meaning in the marketplace. In most cases, suppliers and retailers confuse grape seed extracts as being synonymous with opcs or proanthocyanidins.

However, the terms are not the same in the scientific context. "Grape seed extract" is a nonscientific term that has no specific meaning—other than crushed seeds which can be toxic and oxidizing if not properly manufactured. However, OPCs (short for oligomeric proanthocyanidins) is the active ingredient that was discovered by Dr. Masquelier and proven to have powerful antioxidant properties and other health producing benefits.

It's important to note that independent testing found no active OPCs in a leading American brand of grape seed extract—even though it's labeled and aggressively marketed as a branded OPC product. [More...]

 
Top
Q. Is Flavay™ the same as "grape seed extract" or "pine bark extract"?
A.

Dr. Masquelier's original and only industrial manufacturing plant, located in Gardonne, France.

No.

"Grape seed extract" is a vague, nonspecific term that really has noscientific value. In fact, crude "grape seed extract"  (and "pine bark extract") imitations are virtually worthless to the consumer without active and naturally-derived  oligomeric proanthocyanidins with antioxidant capacity. Some of these extract products contain nothing more than
grape seeds or other plant parts which have been pulverized in a food  processor.

FlavayT, on the other hand, is a very specific molecular complex which is scientifically defined and manufactured  according to the original  process developed and patented by Dr. Jack Masquelier in France, approved as an over-the-counter medicine in France and manufactured under the control  of French Pharmaceutical inspection.

Independent laboratory testing demonstrates that FlavayT scores the highest as an antioxidant and as a free radical  scavenger, which is precisely the free radical scavenging effect that Dr.

More...]

 
Top
Q. Is Flavay™ the same as OPCs (or proanthocyanidins) in the marketplace?
A.

No.

OPCs (short for oligomeric proanthocyanidins) is a term that covers many different and complex molecules. However, due to commercial interests—or by mistake—the terms "OPCs" and "proanthocyanidins" are often abused and misunderstood and have therefore lost all of their scientific meaning in the marketplace.

It's true that "OPCs" is the group of active principles that is responsible for bringing the "grape seed extract" category of products to fame. However, independent testing found no active OPCs in a leading American brand of grape seed extract, even though it's labeled and aggressively marketed as a branded OPC product. [More...]

Consumers should also be aware that some manufacturers of grape seed and pine bark extracts have devised ways to artificially boost the proanthocyanidin numbers for their extracts in a test tube (in vitro, which is outside the living body and in an artificial environment ). However, there is no scientific research to show whether the human body benefits from this artificial boost.

Flavay™ is unique. Flavay™ is derived from the original manufacturing process developed and patented by Dr. Jack Masquelier in France, which captures the naturally-derived oligomeric proanthocyanidins from their plant sources. For well over 50 years, each batch has been routinely and extensively tested and analyzed to guarantee consistency, potency and purity.

Independent laboratory testing demonstrated that Flavay™ scores the highest as an antioxidant and as a free radical scavenger, which is precisely the free radical scavenging effect that Dr. Masquelier invented and claimed in U.S. Patent 4,698,360. [More...]

 
Top
Q. Do you have additional questions about Flavay™?
A.

Click here to submit your question.

 
Top

CLICK HERE TO SEE WHAT THE CUSTOMERS ARE SAYING


Questions?
Please fill in the form below.


First Name:

Last Name:

Mailing Address:

City:

State/Province:

Zip/Postal Code:

Country:

Phone Number:

Email*:

*Sample Email address: name@domain.com


Space here is provided for any questions you may have...


                

[includes/foot_logos_flavay.html]
[includes/foot_links.html]
[includes/foot_disclaimer.html]
REFERENCES:                                                                         Top
Masquelier, J. Plant extract with a proanthocyanidins content as a therapeutic agent having radical scavenging effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa Omega Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers, 1995.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing, Inc., 1997.
Mindell, E., et al. Earl Mindell’s vitamin bible for the 21st century. Warner Books, Inc., 1999.
Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants. Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides. A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des oligomeres procyanidoliques sur des cellules mesenchymateuses en culture. Ii l’attachment des fibres elastiques aux cellules. (Study of the effect of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its heterocyclic ring conformation in solution and the solid state. Journal of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990. pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different procyanidins from grape seeds. Presented at a symposium, “Free radicals in biotechnology and medicine.” Royal Society Of Chemistry, London January 1990, pp. 79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp., 1998.
Braverman, E., et al. The healing nutrients within: in facts, findings and new research. Keats, 1987.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted from ‘vitus vinifera l.’ in the rat. European Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo and in vitro study. Cosmetology Department & S Biovectors, Ramonville St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica, May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l’action d’une substance capillaro-toxique chez des personnes agees--action benefique d’un agnet actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980. pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets des oligomeres du procyanidol sur las resistance capillaire dand l’hypertension arterielle et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24, 1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice de fragilite capillaire dan une population specifique: les sujets cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981. pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand les manifestations fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une etude en double aveugle portant sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100.
Wegrowski, J., Robert, A.M., Maczar, M. The effect of procyanidolic oligomers on the composition of normal and hypercholesterolemic rabbit aortas. Biochem. Pharmacol, (33)21. 1984. pp. 3491-3497.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical activity of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant Research and Journal of Natural Products, July 1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.” pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires” unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and atherothrombosis. Office International Vigne et du Vin, Nutrition and Health Unit, Paris France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131), 1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie. Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+) -catechin becomes resistant to the action of mammalian collagenase.” Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres procyanidoliques sur le lathyrisme experimental chez le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol, (11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4, 177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93, 1988.
Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie. Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453, 1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology. Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5, 1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur l’ulcere gastrique. Resultats, p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley & Sons, Inc., 1999.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members superieurs. Symposium Satellite, Congres International d’Angiologie, Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks of intense training. Abstract submitted to national meeting of the Amer College of Sports Medicine, June 1998.
Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm 43: 385–388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux, 1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation de l’acide ascorbique par les ions cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4) 1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka, I. “Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull. 33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J. “Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase in vitro.” Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies chez le sportif: essai controle de l’Endothelon.” Actualite Therapeutique 90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. “Flavonoids et Pycnogenols” Int J Vit Nut Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol. 25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells of the mouse with Pycnogenol. Cytotest Cell Research GmbH & Co., projects 143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover, Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.

 Contact Us | How to Purchase